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Abstract
There is an urgent need to develop novel markers of pancreatic cancer to facilitate early diagnosis. Pancreatic carci-
noma is characterized by marked stroma formation with a high number of infiltrating tumor-associated macrophages
(TAMs) that originate from circulating mononuclear cells (MNCs). We hypothesized that differential analysis of protein
expression and phosphorylation in circulating MNCs from healthy nude mice and nude mice bearing orthotopic
human pancreatic cancer would identify a surrogate marker of pancreatic cancer. These differences were analyzed
by two-dimensional gel electrophoresis followed by Western blot analysis using antibody against phosphorylated
tyrosine proteins (pY). Protein and phosphorylated protein spots of interest were identified by mass spectrometry
and validated by Western blot analysis as candidate markers for pancreatic cancer. We found that the expression
and phosphorylation of Src family proteins were significantly higher in circulatingMNCs frommice bearing pancreatic
cancer than in circulating MNCs from healthy mice. TAMs in mice with pancreatic tumors also had higher Src family
protein expression and phosphorylation than resident macrophages in the pancreas of healthy mice. The expression
and phosphorylation of Src family proteins were correlated with tumor weight; however, increased Src expression
and phosphorylation also occurred in MNCs from mice with chronic pancreatitis. This is the first report to explore
novel pancreatic tumor markers in circulating MNCs. Although the specificity of the marker for pancreatic cancer
was low, it could be used to monitor the disease or to select high-risk patients with chronic pancreatitis.
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Introduction
Pancreatic cancer, with a 1-year survival rate of 18% and a 5-year sur-
vival rate of less than 3%, is one of the most aggressive malignancies in
humans. The aggressive nature of the disease and the lack of effective
therapy contribute to the high mortality from pancreatic cancer [1,2].
Furthermore, although surgical resection can potentially cure early stage
disease, more than 80% of patients present with locally advanced or
metastatic disease and are thus ineligible for resection [3,4]. Clearly,
there is an urgent need to develop novel biomarkers to detect pancreatic
cancer at an early clinical stage.
Continuous interactions between tumor cells and host stroma cells
are increasingly recognized as being fundamental for tumor cell growth,
invasion, and metastasis [5,6]. The stroma, which occupies 70% to
90% of pancreatic tumors, is a typical histologic finding [7–9]. Among
the cellular components of the stroma, mononuclear cells (MNCs) are
believed to play a central role in the progression and chemoresistance
of tumors [10–13]. Circulating MNCs, predominantly monocytes
and/or macrophages, are recruited into the tumor microenvironment,
where they extravasate and differentiate into tumor-associated macro-
phages (TAMs) [14,15]. Circulating MNCs, whose lifetime is less than
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24 hours, originate in the bone marrow in response to physiologic
and pathologic conditions including cancer [16,17]. These immune
responses may cause a biologic amplification that generates a detectable
response to even small tumors [18]. Therefore, changes in protein expres-
sion and phosphorylation inMNCs could be used to identify a surrogate
marker of the tumor microenvironment [19,20]. The intensity of TAMs
in tumors has been correlated with lymph node metastasis and poor
prognosis in pancreatic cancer patients [21,22], which suggests that
the expression and phosphorylation of certain proteins in MNCs are
surrogate markers of pancreatic cancer.
Here, we propose a new strategy using a nude mouse model of
orthotopic human pancreatic cancer to identify novel markers in cir-
culating MNCs. We hypothesized that the phenotype of circulating
MNCs in tumor-bearing mice is different from the phenotype of cir-
culating MNCs in healthy mice. To test our hypothesis, we used two-
dimensional gel electrophoresis followed by Western blot analysis to
compare differences in MNCs phenotypes. Protein and phosphory-
lated protein spots of interest were excised from the gel, digested, and
analyzed by mass spectrometry, identified using a database search,
and validated by Western blot analysis as candidate markers of pan-
creatic cancer.
Materials and Methods
Cell Lines and Culture Conditions
Human pancreatic cancer cell lines L3.6pl andMPanc96 (kindly pro-
vided by Dr Craig Logsdon, MD Anderson Cancer Center, Houston,
TX) were maintained in minimal essential medium supplemented with
10% fetal bovine serum, sodium pyruvate, nonessential amino acids,
L-glutamine, a two-fold vitamin solution (Life Technologies, Inc, Grand
Island, NY), and a penicillin-streptomycin mixture (Flow Laboratories,
Rockville, MD) as described previously [23]. The cell lines were ex-
amined by Microbiological Associates (Bethesda, MD) and were found
free of mycoplasma, retrovirus type 3, mouse pneumonia virus, mouse
adenovirus, murine hepatitis virus, lymphocytic choriomeningitis virus,
extromelia virus, and lactate dehydrogenase virus. The cell lines were
validated by short tandem repeat (STR) DNA fingerprinting using the
AmpFℓSTR Identifiler PCR Amplification Kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instructions. STR
profiles were compared with known American Type Culture Collection
fingerprints (ATCC.org), the Cell Line IntegratedMolecular Authentica-
tion database version 0.1.200808 (http://bioinformatics.istge.it/clima/)
(Nucleic Acids Research 37:D925-D932 PMCID: PMC2686526),
and the MD Anderson fingerprint database.
Primary Antibodies
Unconjugated rat anti–mouse F4/80 and Alexa 647–labeled rat anti–
mouse F4/80 antibodies were obtained from AbD Serotec (Raleigh,
NC), rabbit anti–Src antibody was from Cell Signaling Technology
(Danvers, MA), rabbit anti–human phospho-Src (Y419) antibody was
from R&D Systems (Minneapolis, MN), and anti–α-smooth muscle
actin (α-SMA) was fromDako (Carpinteria, CA). Anti–phosphotyrosine,
recombinant clone 4G10 was from Millipore (Billerica, MA).
Pancreatic Cancer Specimen of Patients
We obtained human pancreatic cancer specimens from patients
treated at MD Anderson. Patients provided written informed consents.
Animals
Male athymic nude (NCI-nu) mice were purchased from the Animal
Production Area of the National Cancer Institute, Frederick Cancer
Research Facility and Development Center (Frederick, MD). The mice
were housed and maintained under specific pathogen-free conditions
in facilities approved by the American Association for Accreditation of
Laboratory Animal Care and in accordance with the current regulations
and standards of the US Department of Agriculture, US Department
of Health and Human Services, and National Institutes of Health.
The mice were used when they were 8 to 12 weeks old in accordance
with institutional guidelines.
Orthotopic Implantation of Tumor Cells
We harvested L3.6pl and MPanc96 cells from subconfluent cultures
by briefly exposing the cultures to 0.25% trypsin and 0.02% EDTA.
Trypsinization was stopped with medium containing 10% fetal bovine
serum, and the cells were washed once in serum-free medium and
resuspended in Hank’s balanced salt solution. To produce pancreatic
tumors, we injected 5 × 104 or 1 × 106 cells of greater than 90% via-
bility into the pancreas of nude mice as described previously [23].
Necropsy Procedures, Blood Collection, and Histologic Studies
Blood and tumor samples were collected from the mice 3 weeks after
the injection of 1 × 106 cells or 12 weeks after the injection of 5 ×
104 cells. The mice were anesthetized using isoflurane, and blood sam-
ples were collected from the retro orbit into tubes to which heparin (BD
Biosciences, San Jose, CA), phosphatase inhibitor cocktail (PhosSTOP;
Roche Applied Science, Mannheim, Germany), and complete mini
EDTA-free protease inhibitor cocktail tablets (Roche Applied Science)
had been added. The mice were then killed by cervical dislocation, and
tumors growing in the pancreas were excised and weighed, fixed in 10%
formalin or embedded in Optimal Cutting Temperature compound
(Miles, Inc, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored
at −80°C.
Inducing Chronic Pancreatitis in Mice
Chronic pancreatitis was induced in mice (n = 5) with six hourly
intraperitoneal injections of 50 μg/kg of cerulein (Sigma-Aldrich, Inc,
St Louis, MO) 3 days a week for 6 weeks [24]. Two days after the final
cerulean injection, blood samples were collected, the mice were killed,
and their pancreases were harvested.
Mononuclear Cell Fractionation from Whole Blood
Blood samples from five healthy mice and five tumor-bearing mice,
respectively, were pooled, applied toHistopaque-1077 (Sigma-Aldrich),
and centrifuged at 1000g for 15 minutes at 22°C to collect MNCs [25].
For purification, MNC fractions were transferred and washed three
times with ice-cold phosphate-buffered saline (PBS).
Western Blot Analysis
Proteins were extracted from purifiedMNCs by applying lysis buffer
(7Murea, 2M thiourea, 4%CHAPS, 1%DTT, PhosSTOP, and com-
plete mini EDTA-free protease cocktail inhibitor tablets) to MNCs
and then centrifuged for 15 minutes at 18,000g. Lysates were re-
solved on 7.5% SDS-PAGE and transferred to 0.45-μm nitrocellulose
membranes using the iBlot Dry Blotting System (Invitrogen, Carlsbad,
CA). The membranes were blocked with 5% nonfat dry milk in
Tween-Tris–buffered saline and incubated overnight at 4°C with the
indicated primary antibodies. After the membranes were washed,
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immunodetection was performed using the corresponding secondary
horseradish peroxidase–conjugated antibodies for 1 hour at room
temperature. Immunolabeling was detected by enhanced chemilumi-
nescence (GE Healthcare, Piscataway, NJ) according to the manufac-
turer’s instructions [23].
Two-dimensional Gel Electrophoresis
Proteins extracted from purified MNCs were washed and precipi-
tated using a 2-D Clean Up Kit (Bio-Rad Laboratories, Hercules,
CA), resuspended in isoelectric focusing (IEF) buffers, and quantified
by RC DC protein assay (Bio-Rad Laboratories).
Immobilized pH gradient strips (pH, 3-10; length, 11 cm; Bio-Rad
Laboratories) were rehydrated passively overnight with IEF buffer con-
taining 50 μg of proteins extracted from purified MNCs. The IEF run
was carried out as follows: 500 V for 1 hour, linear ramp to 8000 V for
2.5 hours, 8000 V for 350,000 V-h, and hold at 500 V. Individual
strips were equilibrated in equilibration buffers I and II (Bio-Rad Lab-
oratories) for 20 minutes. Protein separation by the second dimension
was carried out by 12% SDS-PAGE at a constant 200 V per gel. Pro-
teins were stained with SYPRO Ruby (Invitrogen), which allowed the
intensity of the protein spot to be directly correlated with the quantity
of protein present [26–28]. The same protein samples were simulta-
neously separated by two-dimensional gel electrophoresis, transferred
to nitrocellulose membranes, and subjected to Western blot analysis
as described previously.
Image Analysis and Differential Analysis
SYPRORuby–stained gels were digitized using a Fluor-SMultiImager
(Bio-Rad Laboratories). Differential analysis of the gel images was per-
formed using PDQuest version 8.0 software (Bio-Rad Laboratories).
In brief, gel images were automatically processed for noise reduction,
background subtraction, spot detection, quantification, and gel-to-gel
matching, and the quantity of an individual protein spot was normalized
to the total quantity of all valid spots; that is, the normalized intensities
were calculated as the intensities of a particular spot from the intensities
of all the spots of the gel and expressed as parts per million. The normal-
ized quantity data were exported to Excel 2003 (Microsoft, Seattle, WA),
and the means and SDs of spot intensity were calculated [29,30].
Protein Sequencing and Identification
Selected protein spots were excised manually with a scalpel. Gel
pieces were washed, destained, and digested in-gel with 200 ng
of sequencing-grade modified trypsin (Promega, Madison, WI) for
18 hours at 37°C. The resulting peptides were extracted and analyzed
using a Nano-LC-MS/MS with online desalting. The Nano-LC system
consisted of a Famos autosampler, an Ultimate Nano-LC module, and
a Switchos precolumn switching device (LC-Packings/Dionex Corp.,
Sunnyvale, CA) with a 75-μm ID C18-column as the analytical
column and a 0.3 × 5-mm C18 desalting column (both from LC-
Packings) plumbed on the Switchos for online desalting. Samples were
injected using the “microliter pickup” method, which allowed all of the
liquid removed from the sample vial to be sandwich-loaded into the
sample loop and then injected onto the desalting column at 40 μl/
min in 2% acetonitrile/water containing 0.01% trifluoroacetic acid.
The separation column was operated at a flow rate of approximately
200 nl/min, equilibrated in 5% acetonitrile before injection, and
eluted with a linear acetonitrile gradient of 30% or 40% followed by
a wash at 65% acetonitrile containing 0.01% trifluoroacetic acid and
re-equilibration in initial conditions. Column effluent was introduced
to the mass spectrometer using the ThermoFinnigan NanoSpray source
fitted with a spray tip from New Objective (New York, NY). Electro-
spray ion trap mass spectrometry was performed on a linear ion trap
mass spectrometer (LTQ; Thermo, San Jose, CA). Typical settings were
as follows: spray tip voltage, 2000 V; inlet tube temperature, 120°C;
tube voltage, 100 V; and tube lens offset voltage, 20 V. We typically
performed one survey scan followed by three data-dependent MS/
MS scans using collision-induced dissociation to induce fragmentation.
Database Search
We identified proteins by using Mascot (version 2.1; Matrix Science,
London, UK) to perform a database search of the fragment spectra
against the National Center for Biotechnology Information’s non-
redundant protein database, which is updated monthly. Typical search
settings were the following: enzyme, trypsin, two missed cleavages
allowed; mass error, 2d parent, 1d fragments; modifications, Met oxi-
dation. Homologies were identified using the Basic Local Alignment
Search Tool (BLAST).
Immunohistochemical Analysis to Detect α-SMA in
Pancreatic Tumors
Clinical specimens or paraffin-embedded pancreatic tumors from
mice were immunostained to evaluate the expression of α-SMA.
Sections were deparaffinized in xylene, dehydrated with alcohol, and
rehydrated in PBS. Endogenous peroxidase was blocked with 3%
hydrogen peroxide in PBS. Samples were exposed to protein block
(5% normal horse serum and 1% normal goat serum in PBS) and
incubated overnight at 4°C with the primary antibodies. After incuba-
tion at room temperature with peroxidase-conjugated secondary anti-
body for 1 hour, positive reaction was detected by exposure to stable
3,3′-diaminobenzidine (Phoenix Biotechnologies, Huntsville, AL).
Slides were counterstained with Gill’s no. 3 hematoxylin. Sections
stained for α-SMA or hematoxylin and eosin were examined using a
NikonMicrophot-FXmicroscope (Nikon, Inc., Melville, NY) equipped
with a three-chip charge-coupled device color videocamera (Model
DXC990; Sony Corp., Tokyo, Japan). Digital images were captured
using Optimas Image Analysis software (Media Cybernetics, Silver
Spring, MD).
Immunofluorescence Staining for F4/80, Src, and
Phosphorylated Src Family Proteins
Frozen tissues were sectioned (8- to 10-μm thickness) and fixed in
cold acetone for 5 minutes, in 1:1 acetone-chloroform (vol/vol) for
5 minutes, and again in cold acetone for 5 minutes. The sections were
then exposed to protein block (5% normal horse serum and 1% normal
goat serum in PBS) and incubated with each primary antibody at the
appropriate dilution overnight at 4°C. Immunofluorescence staining
was done using a corresponding fluorescent secondary antibody as
previously described [23]. For double immunofluorescence staining,
such as F4/80 and Src or F4/80 and phosphorylated Src family pro-
teins, samples were stained overnight with an antibody to Src or to
the phosphorylated Src family protein followed by 1-hour staining with
Cy2-labeled donkey anti–rabbit secondary antibody (1:500; Molec-
ular Probes, Carlsbad, CA) at room temperature. The sections were
then briefly blocked in a blocking solution and stained for 3 hours
with Alexa 647–labeled F4/80 antibody at room temperature. The
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slides were rinsed, and the images were captured and analyzed by
confocal microscopy (Carl Zeiss MicroImaging, Inc, Thornwood,
NY). Src or phosphorylated Src family proteins presented as green fluo-
rescence, and F4/80–positive monocytes and macrophages presented
as red fluorescence. The expression of Src or phosphorylated Src family
proteins on F4/80–positive monocytes and macrophages was detected
by the colocalization of green and red fluorescence, which produced
yellow fluorescence.
Statistical Analysis
The Student’s t test was used to compare protein spot intensity.
P < .05 was considered statistically significant.
Results
Orthotopic Human Pancreatic Cancer in Nude Mice
Whereas the routine injection of 1 × 106 human pancreatic cancer
cells into the pancreas of nude mice produced 8- to 10-mm tumors
in 2 to 3 weeks (acute disease model), the injection of 5 × 104 cells
produced 8- to 10-mm tumors in the pancreas in 12 to 14 weeks
(chronic disease model). Hematoxylin and eosin staining of the tumors
revealed that the chronic disease model had more stromal formation
with MNCs infiltration than the acute disease model.
Diffuse SMA deposits, which are a marker of stroma formation,
were confirmed in the specimens from pancreatic cancer patients.
In the rapidly growing tumors of the acute disease model, limited
levels of SMA deposits surrounded the expanding tumors. In contrast,
diffuse and strong SMA expression was found in the slowly growing
tumors of the chronic disease model (Figure 1). Because the findings
in the chronic disease model were more similar than those in the acute
disease model to the findings in the specimens from pancreatic cancer
patients, we used the chronic disease model to identify novel markers
of pancreatic cancer.
Protein Expression and Phosphorylation in MNCs of
Mouse Model
Peripheral blood samples from five healthy mice or five mice bear-
ing slow-growing tumors (chronic disease model) were respectively
pooled. MNCs were purified from each pool, and the proteins were
extracted. Fifty micrograms of each protein was separated by two-
dimensional gel electrophoresis (repeated four times). The proteins
in the gels were visualized by staining the gels with SYPRO Ruby,
and the differential analysis of the gel images was performed by PD
QUEST as described in Materials and Methods (Figure 2A). The pro-
gram automatically detected more than 1000 protein spots on each
gel, and approximately 800 of the spots were matched among the gels.
Several protein spots had expression levels that differed significantly
between healthy and tumor-bearing mice, and these spots were con-
firmed by visual examination of gel images (data not shown). Among
these, protein spots (indicated by an arrow in Figure 2A) exhibited
significantly higher intensities in the MNCs from tumor-bearing mice
than in the MNCs from healthy mice (Figure 2B). The same protein
samples were simultaneously separated by two-dimensional gel electro-
phoresis, transferred to nitrocellulose membrane, and Western blot
analysis was performed using antibody to pY. Western blot revealed
that tyrosine phosphorylation of proteins was markedly higher in
the MNCs of tumor-bearing mice than in the MNCs of healthy mice
(Figure 2C ). The location of the strongest phosphorylated protein was
identical to the protein spots of interest in the SYPRO Ruby–stained
gels (Figure 2, A and C).
Identification of the Protein Spot of Interest
The protein spots of interest were manually excised from the gel,
and amino acid sequence was determined by LC-MS/MS. The mass
spectra were searched using Mascot (in-house server), and 35 candi-
date proteins were identified in the protein spots of interest. Among
these proteins, we focused on Lyn and Fgr, which are Src family
kinases that have important roles in the activation, migration, and
Figure 1. Hematoxylin and eosin and α-SMA staining of orthotopic human pancreatic cancer in nude mice and clinical specimens from
pancreatic cancer patients. Rapidly growing “acute” tumors (less stroma) were established 3 weeks after the injection of 1 × 106, and
slow-growing “chronic” tumors (abundant stroma) were established 12 to 14 weeks after the injection of 5 × 104 L3.6pl or MPanc96
human pancreatic cancer cells into the pancreas of nude mice. The slow-growing tumors had stroma similar to clinical pancreatic cancer
specimen. Bar, 50 μm.
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Figure 2. Differential analysis by two-dimensional gel electrophoresis followed by Western blot analysis using antibody against phosphor-
ylated tyrosine proteins (pY). (A) Protein mixtures in circulating MNCs of healthy mice or tumor-bearing mice were separated by two-
dimensional gel electrophoresis. The gels were stainedwith SYPRORuby to evaluate protein expression. One of the protein spots (indicated
with a red oval) had a significant increase in intensity. (B) Tumor-bearingmice (n=4) had significantly higher normalized intensities of protein
spots (indicated by an arrow in A) than healthy mice (n = 4) (Student’s t test, P < .05). (C) Proteins in the gels were transferred to a nitro-
cellulose membrane, and Western blot analysis was performed against antibody to pY. Tyrosine phosphorylation of proteins was markedly
higher in the MNCs of tumor-bearing mice than in the MNCs of healthy mice, especially in the area indicated with red oval. The locations
of protein spots of interest and phosphorylated protein spots of interest were identical (A and C). These results are representative of four
independent experiments.
Figure 3. Validation by Western blot analysis. (A) Protein samples in MNCs were subjected to two-dimensional gel electrophoresis
followed by Western blot analysis using an antibody to Src (“WB: anti–Src Ab”) and phosphorylated Src family proteins (“WB: anti–
phospho Src Ab”). (B) Expression and phosphorylation of Src family proteins (determined by Western blot analysis) were higher in cir-
culating MNCs of tumor-bearing mice than healthy mice. Furthermore, the expression and phosphorylation of Src family proteins were
higher in the MNCs of mice bearing chronic disease tumors than in MNCs of mice bearing acute disease tumors. The results are rep-
resentative of two independent experiments.
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extravasation of monocytes and macrophages [31]. A specific anti-
body against Lyn and Fgr and their phosphorylated forms with
satisfactory quality have not been available. Therefore, we used anti-
bodies against Src and phosphorylated Src family proteins, which
would cross-react with Lyn, Fgr, and their phosphorylated forms.
Western Blot Validation
Two-dimensional gel electrophoresis and SDS-PAGE followed by
Western blot analysis revealed that immunoreaction to Src antibody
occurred at the same location as the protein spots of interest in the
gels (indicated with red oval, Figures 2A and 3A). The immuno-
reaction to phosphorylated Src family antibody was similar to the
interaction to pY antibody (indicated with red oval, Figures 2C
and 3A). Expression and phosphorylation of Src family proteins were
higher in the MNCs of tumor-bearing mice than in the MNCs of
healthy mice. Although tumors in the acute disease and chronic dis-
ease models were similar in weight (data not shown), circulating
MNCs in mice with chronic disease had higher Src family protein
expression and phosphorylation (Figure 3B).
Infiltration of Monocytes/Macrophages and Expression and
Phosphorylation of Src Family Proteins in Normal Pancreas
and Orthotopic Human Pancreatic Tumors in Nude Mice
Circulating MNCs, predominantly monocytes and macrophages,
are precursors of TAMs and could reflect the immediate past of the
tumor microenvironment [16,17]. To examine correlation of the
expression and phosphorylation of Src family proteins in between
circulating MNCs and TAMs, normal pancreas and pancreatic tumor
(chronic disease) in nude mice were stained with antibodies to F4/80
(marker of monocytes/macrophage), Src, and phosphorylated Src
family proteins. Staining normal pancreas with antibodies revealed
very few cells expressing F4/80 (Figure 4A), Src, or phosphorylated
Src (data not shown). In contrast, staining pancreatic tumors in nude
Figure 4. Validation by immunofluorescence staining. (A) Immunofluorescence staining using an F4/80 antibody of a normal pancreas
and a pancreas with a chronic disease tumor (L3.6pl) in nude mice. Nuclei were stained with topro3 (blue fluorescence). Bar, 50 μm. (B)
Immunofluorescence staining using an F4/80 antibody of a chronic disease tumor (L3.6pl) in the pancreas of nude mice (red fluores-
cence), Src (green fluorescence), and phosphorylated Src family proteins (P-Src, green fluorescence). F4/80–positive TAMs expressed
Src, which was phosphorylated in the tumor microenvironment. Bar, 20 μm.
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mice revealed numerous F4/80–positive cells, i.e., TAMs, surrounding
L3.6pl, human pancreatic cancer cells (Figure 4A). We observed in-
creased expression and phosphorylation of Src family proteins in sur-
rounding stroma cells. Double immunofluorescence staining revealed
that F4/80–positive TAMs expressed Src and phosphorylated Src family
proteins (Figure 4B).
Effect of Soluble Factors from Plasma of Tumor-Bearing
Mice on Src Expression and Phosphorylation of
Normal MNCs
Incubating circulating MNCs from the blood of healthy mice for
15 minutes with plasma from healthy mice or tumor-bearing mice
in vitro revealed that although plasma from healthy mice did not alter
the phosphorylation of Src family proteins, the plasma from tumor-
bearing mice increased phosphorylation (Figure 5). The expression
level of Src proteins did not change.
Sensitivity and Specificity of Src and Phosphorylated Src
Family Proteins as Markers for Pancreatic Cancer
In our final experiment, we examined the sensitivity and specificity
of Src and phosphorylated Src family proteins as marker(s) for pan-
creatic cancer. We evaluated the correlation between pancreatic tumor
weight and expression and phosphorylation of Src family proteins in
circulating MNCs. Blood samples of five healthy mice or five tumor-
bearing mice of different median weights (0.15, 0.40, 1.12, or 2.75 g;
n = 5) were pooled to obtain a sufficient amount of proteins for analy-
sis. An increase of expression and phosphorylation of Src family
proteins correlated to tumor weight. The increases were found in cir-
culating MNCs of mice bearing the smallest pancreatic tumor (0.15 g;
Figure 6, A and B).
Immunofluorescence staining of phosphorylated Src family proteins
in the pancreas of mice with induced chronic pancreatitis revealed in-
creased infiltration of F4/80–positive cells expressing phosphorylated
Src family proteins (Figure 6C). Western blot analysis of the proteins
in MNCs revealed increased expression and phosphorylation of Src
family proteins in tumor-bearing mice as well as in mice with chronic
pancreatitis, suggesting that Src protein expression was not sufficiently
specific to serve as a marker for pancreatic cancer (Figure 6D).
Discussion
There is an urgent need to find a new biomarker for pancreatic cancer.
To date, the American Society of Clinical Oncology Tumor Markers
Expert Panel has not recommended a biomarker in plasma or serum
for screening for and/or diagnosing pancreatic cancer [32]. Analyzing
protein expression in immune cells could provide new perspectives
on understanding the host response to pathologic conditions, such as
inflammatory disease and cancer. However, protein expression does not
necessarily reflect protein activity. The activity of cells is often regulated
by posttranslation modifications, of which phosphorylation is one of
the most prominent [33,34]. In the current study, the differential analy-
sis of protein expression and phosphorylation in the MNCs of tumor-
bearing mice and healthy mice revealed Src and phosphorylated Src
family proteins as candidate markers for pancreatic cancer.
A number of mechanisms may have increased the phosphorylation
of Src family proteins in MNCs. The tumor microenvironment and/or
host organs may have released soluble factors that stimulated MNCs to
phosphorylate Src family proteins (Figure 5). Furthermore, monocytes
and/or macrophages infected by Listeria monocytogenes at peripheral
infection sites have been reported to reenter the circulation and could
return to the bone marrow [35], indicating the possibility that TAMs
also reenter the circulation. If this was the case in the current study,
circulating MNCs could have originated from both the bone marrow
and the tumor microenvironment, which would support our rationale
for investigating the phenotypes of circulating MNCs as surrogate
markers of the tumor microenvironment.
Unlike the acute disease model after routine injection of 1 × 106 cells
into the pancreas of mice, when 5 × 104 viable cells were injected,
similar size tumors developed after 3 months (chronic disease model).
Because an increased expression of SMA (a stromal marker), which is
a characteristic finding in patients with pancreatic cancer, was found in
the chronic but not the acute disease model, we used the chronic dis-
ease model to explore novel markers for pancreatic cancer. Indeed, Src
expression and phosphorylation in circulating MNCs were higher in
the chronic disease model than in the acute disease model, which sug-
gests a close relationship between the amount of stroma formation in
the pancreatic tumor and the level of Src expression and phosphoryla-
tion in circulating MNCs.
Src family kinases (Src, Blk, Fgr, Fyn, Hck Lck Yes, and Lyn) have
been detected in hematopoietic cells to varying degrees [31]. These
protein kinases may play a central role in regulating recruitment, migra-
tion, survival, cytokine production, reactive oxygen species production,
and phagocytosis in monocytes and/or macrophages. Macrophages
with a genetic deficiency of Src family kinases show marked decreased
recruitment to inflammatory sites in vivo and reduced migration abil-
ity in wound healing and transwell migration assays [36]. These data
Figure 5. Western blot analysis of Src expression (Src) and phos-
phorylation (P-Src) in the circulating MNCs of healthy mice incubated
with the plasma of healthy mice or plasma of tumor-bearing mice for
15 minutes. Plasma from healthy mice did not alter the phosphoryla-
tion of Src family proteins. In contrast, plasma from tumor-bearing
mice increased Src phosphorylation. The expression levels of Src
proteins did not change. These results are representative of three
independent experiments.
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support our hypothesis that circulating MNCs and TAMs in tumor-
bearing mice (with increased expression and phosphorylation of Src
family proteins) have a phenotype distinct from that of MNCs and
resident macrophages in healthy mice.
To determine whether expression and phosphorylation of Src family
proteins were a specific immune response only to pancreatic tumor,
we developed a mouse model with chronic pancreatitis. Expression
and phosphorylation of the proteins were also elevated in the circulating
MNCs of pancreatitis mouse model. There was also increased infiltra-
tion of monocytes/macrophages expressing phosphorylated Src family
proteins into the pancreas with chronic pancreatitis compared with
normal pancreas. Although these results indicated that Src family pro-
teins have low specificity as unique markers of pancreatic cancer, Src
family proteins could, nevertheless, be used to identify patients at high
risk of developing pancreatic cancer because pancreatic cancer occurs
16 to 27 times more often in patients with chronic pancreatitis than
in healthy individuals [37,38]. Furthermore, these markers could be
used to monitor the efficacy of therapy for pancreatic cancer. On
treatment with an effective therapy, the number of apoptotic cells in
a tumor will increase, which may in turn lead to tumor regression
[20]. The apoptotic cells are eliminated up by activated TAMs, and
these reactions can further influence immune response [19] and can
be accompanied by increased expression and phosphorylation of Src
family proteins in circulating MNCs. There are still a number of
protein and phosphorylated protein spots of interest differentially ex-
pressed by MNCs in healthy and tumor-bearing mice. Identification
of these proteins and validation as a novel marker of pancreatic cancer
are under active investigation.
In summary, differential analysis of protein expression and phos-
phorylation in circulating MNCs of healthy mice and tumor-bearing
mice identified Src and phosphorylated Src family proteins as candi-
date surrogate markers of the tumor microenvironment. We have iden-
tified circulating MNCs as a source of novel biomarkers with strong
possibility of providing proteomic and phosphoproteomic features in
Figure 6. Sensitivity and specificity of Src and phosphorylated Src family proteins as markers for pancreatic cancer. (A) The expression and
phosphorylation of Src family proteins (Src, P-Src) in the MNCs of healthy mice and mice bearing L3.6pl chronic disease tumors of various
weights were evaluated byWestern blot analysis using antibodies to Src family proteins. (B) There was a tumor weight–dependent increase
of Src family protein phosphorylation. (C) Hematoxylin and eosin staining and immunofluorescence staining with antibodies to F4/80 and
phosphorylated Src family proteins (P-Src) of normal pancreas and chronic pancreatitis. The pancreas of mice with chronic pancreatitis had
increased infiltration of F4/80–positive cells, expressing phosphorylated Src family proteins, compared with pancreas of healthy mice. Bar,
50 μm. (D) Western blot analysis of proteins in circulating MNCs of healthy mice, tumor-bearing mice (chronic disease), and mice with
chronic pancreatitis. MNCs from mice with pancreatitis and tumor-bearing mice had higher expression and phosphorylation of Src family
proteins (Src, P-Src) than MNCs from healthy mice. These results are representative of two independent experiments.
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mice with various diseases. Therefore, this approach provides consid-
erable value in exploring new ways to identify novel biomarkers in
future studies.
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